Publications by authors named "Judith Karp"

Claim this Profile
G
Genomic testing and patient rights.
C Michael Jones, Judith Karp, Dena S Davis

J Natl Cancer Inst· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic review and meta-analysis: Prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia.
Stephanie Franco, Xue Geng, Valeriy Korostyshevskiy, Judith E Karp, Catherine Lai

Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification.
Michael J Hochman, Megan Othus, Robert P Hasserjian, Alex Ambinder, Andrew Brunner, Judith E Karp

Leukemia· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethics and Clinical Research: Improving Transparency and Informed Consent in Phase I Oncology Trials.
Paul H Frankel, Susan Groshen, Jan H Beumer, Laura Cleveland, Edward S Kim, Judith E Karp

J Clin Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?
Michael R Cook, Judith E Karp, Catherine Lai

EJHaem· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia.
Kimberley Doucette, Mary-Elizabeth Percival, Lacey Williams, Adrese Kandahari, Allison Taylor, Judith E Karp

Hematol Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
Selina M Luger, Victoria X Wang, Jacob M Rowe, Mark R Litzow, Elisabeth Paietta, Judith Karp

Leuk Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia.
Hetty E Carraway, Yazeed Sawalha, Ivana Gojo, Min-Jung Lee, Sunmin Lee, Judith E Karp

Leuk Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.
Lacey Williams, Kimberley Doucette, Judith E Karp, Catherine Lai

Bone Marrow Transplant· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia.
Husheng Ding, Nicole D Vincelette, Cordelia D McGehee, Mira A Kohorst, Brian D Koh, Judith E Karp

Cancer Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in therapeutic options for newly diagnosed, high-risk AML patients.
Kimberley Doucette, Judith Karp, Catherine Lai

Ther Adv Hematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS.
Joshua F Zeidner, Hanna A Knaus, Amer M Zeidan, Amanda L Blackford, Raul Montiel-Esparza, Judith E Karp

Leukemia· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Elihu Estey, Judith E Karp, Ashkan Emadi, Megan Othus, Robert Peter Gale

Leukemia· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.
Keith W Pratz, Michelle A Rudek, B Douglas Smith, Judith Karp, Ivana Gojo

Biol Blood Marrow Transplant· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting TCTP with Sertraline and Thioridazine in Cancer Treatment.
Robert Amson, Christian Auclair, Fabrice André, Judith Karp, Adam Telerman

Results Probl Cell Differ· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
Renu Singh, Shailly Mehrotra, Mathangi Gopalakrishnan, Ivana Gojo, Judith E Karp

Cancer Chemother Pharmacol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Mark R Litzow, Xin V Wang, Martin P Carroll, Judith E Karp, Rhett P Ketterling

Am J Hematol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.
Hanna A Knaus, Sofia Berglund, Hubert Hackl, Amanda L Blackford, Joshua F Zeidner, Judith E Karp

JCI Insight· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).
Joshua F Zeidner, Matthew C Foster, Amanda L Blackford, Mark R Litzow, Lawrence E Morris, Judith E Karp

Leuk Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies.
Shailly Mehrotra, Mathangi Gopalakrishnan, Jogarao Gobburu, Jiuping Ji, Jacqueline M Greer, Judith E Karp

Clin Cancer Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.
Kelly J Norsworthy, Amy E DeZern, Hua-Ling Tsai, Wesley A Hand, Ravi Varadhan, Judith E Karp

Leuk Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
Jonathan A Webster, Raoul Tibes, Larry Morris, Amanda L Blackford, Mark Litzow, Judith E Karp

Leuk Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.
Carl LaCerte, Vijay Ivaturi, Joga Gobburu, Jacqueline M Greer, L Austin Doyle, Judith E Karp

Clin Cancer Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments.
Jennifer Ding, Judith E Karp, Ashkan Emadi

Cancer Biomark· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.
Katherine L B Knorr, Laura E Finn, B Douglas Smith, Allan D Hess, James M Foran, Judith E Karp

Stem Cells Transl Med· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis